ClinicalTrialsFinder
RecruitingPhase 2NCT06852638

CD70-targeted immunoPET Imaging of Malignant Cancers

CD70-targeted PET/ CT in the Diagnosis of Malignant Cancers

Sponsor

RenJi Hospital

Enrollment

300 participants

Start Date

Dec 23, 2024

Study Type

INTERVENTIONAL

Conditions

LymphomaRenal CancerMantle Cell LymphomaNasopharyngeal CarcinomaFollicular LymphomaRenal Clear Cell CarcinomaLymphoma, Large B-Cell, Diffuse

Summary

This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new type of PET imaging scan that uses a special tracer to better detect certain cancers — including kidney cancer, lymphoma, and nasopharyngeal carcinoma (a type of head and neck cancer). The goal is to see how well this new imaging technique identifies these tumors. **You may be eligible if:** - You are between 18 and 80 years old - You have been diagnosed with or are suspected to have kidney cancer (especially clear cell renal cell carcinoma), lymphoma, or nasopharyngeal carcinoma - You are able to give informed consent **You may NOT be eligible if:** - You are pregnant - You have severe liver or kidney failure - You have a known allergy to the type of imaging agent used in this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[18F]F-RESCA-RCCB6

Enrolled patients will receive 0.01-0.1 mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.

DRUG[18F]F-RESCA-R8B4

Enrolled patients will receive 0.01-0.1 mCi/kg of \[18F\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]R8B4 injection.

DRUG[68Ga]Ga-NOTA-R8B4

Enrolled patients will receive 0.01-0.1 mCi/kg of \[68Ga\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]R8B4 injection.

DRUG[18F]F-RESCA-RD06

Enrolled patients will receive 0.01-0.1 mCi/kg of \[18F\]F-RESCA-RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RD06 injection.

DRUG[68Ga]Ga-NOTA-RD06

Enrolled patients will receive 0.01-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RD06 injection.

Locations(1)

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06852638

Related Trials

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT032236101 location

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

NCT075131291 location

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

NCT066824421 location

64Cu-LLP2A for Imaging Hematologic Malignancies

NCT066361751 location

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT000268841 location